Lund, Anne Mathilde1; Kaas, Christian Schrøder5; Kildegaard, Helene Faustrup3; Kristensen, Claus5; Andersen, Mikael Rørdam1
1 Department of Systems Biology, Technical University of Denmark2 Network Engineering of Eukaryotic Cell Factories, Department of Systems Biology, Technical University of Denmark3 Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark4 Center for Microbial Biotechnology, Department of Systems Biology, Technical University of Denmark5 Novo Nordisk A/S
The Chinese hamster ovary (CHO) cell-line is the predominant mammalian industrial cell line being used to produce recombinant therapeutic proteins. Although CHO cells have been used for more than 25 years, the genome sequence was first published in 2011. So far there have been limited studies of the cell biology of the CHO cell and the potential of cell line engineering. To elucidate the poorly understood cellular processes that control and limit recombinant protein production and secretion, a system-wide study was initiated to identify possible engineering targets relevant for therapeutic protein production.
Main Research Area:
3rd Annual Next Generation Sequencing Asia Congress, 2013